InvestorsHub Logo
Post# of 24568
Next 10
Followers 2
Posts 932
Boards Moderated 0
Alias Born 12/12/2009

Re: None

Monday, 10/25/2010 1:53:20 PM

Monday, October 25, 2010 1:53:20 PM

Post# of 24568
AVNR($3.07) How many here will be holding their
long position thru the weekend?

Barring any unforseen circumstances between now and the 30th, I'll be holding 100%.

Thanks for all of the intelligent and well thought out analysis from this board.

Another reason I believe approval is imminent is something I read on the ymb over the weekend...

"QT intervals pose no problem - This is not AMLN/ALKS"

Put yourselves in the FDA panels' shoes and think about this carefully...

AVP-923 is a treatment for a patient population with a terminal condition. The vast majority of these poor souls haven't the slightest glimmer of hope in their prognosis, and, unfortunately, because of their condition they are subject to ridicule and humiliation on a daily basis.

A significant numbert of these sufferers become reclusive and often chose total isolation from friends and family and society in general rather than risk a potentially sudden and embarrasing outburst. A sad situation to say the least. This was simply not the case with the AMLN patient population.

Which brings me to my point. The FDA is not the "heartless", cold, evil entity that many make it out to be (those people are referred to as 'shorts') and keep in mind they have an extremely tough 'row-to-hoe'.

It is therefore my conclusion that the FDA will lean in favor of the 'quality of life' scenario and approve this drug so that those who are afflicted with these various debilitating conditions can live out the rest of their shortened lives with the honor and dignity they all truly deserve.

I know I would give them this gift and I know most of you reading these words would as well.

The QT's be damned.

GLTAL

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.